WHO ICTRP trial
Phase II trial of anti-PD-1 therapy after anti-PD-L1 therapy in patients with…
JPRN-UMIN000040696 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000040696 |
|---|---|
| Public title | Phase II trial of anti-PD-1 therapy after anti-PD-L1 therapy in patients with unresectable locally advanced or advanced non-small-cell lung cancer |
| Scientific title | Phase II trial of anti-PD-1 therapy after anti-PD-L1 therapy in patients with unresectable locally advanced or advanced non-small-cell lung cancer - Phase II trial of anti-PD-1 therapy after anti-PD-L1 therapy |
| Primary sponsor | National cancer center hospital |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | Japan |
| Conditions | non-small-cell lung cancer |
| Interventions | Pembrolizumab (200mg/body q3w)or Nivolumab (240mg/body q2w) |
| Registration date | Sep 6, 2020 |
| Target size | 75 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: